Burrage Capital Management 13F annual report
Burrage Capital Management is an investment fund managing more than $99.7 million ran by Jeff Crispen. There are currently 22 companies in Mr. Crispen’s portfolio. The largest investments include Biocryst Pharmaceuticals and Intellia Therapeutics Inc, together worth $24 million.
$99.7 million Assets Under Management (AUM)
As of 9th August 2021, Burrage Capital Management’s top holding is 864,916 shares of Biocryst Pharmaceuticals currently worth over $13.7 million and making up 13.7% of the portfolio value.
Relative to the number of outstanding shares of Biocryst Pharmaceuticals, Burrage Capital Management owns more than approximately 0.1% of the company.
In addition, the fund holds 63,634 shares of Intellia Therapeutics Inc worth $10.3 million, whose value grew 128.0% in the past six months.
The third-largest holding is Epizyme Inc worth $6.95 million and the next is Essa Pharma Inc worth $6.78 million, with 237,442 shares owned.
Currently, Burrage Capital Management's portfolio is worth at least $99.7 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Burrage Capital Management
The Burrage Capital Management office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Jeff Crispen serves as the Chief Financial Officer at Burrage Capital Management.
Recent trades
In the most recent 13F filing, Burrage Capital Management revealed that it had opened a new position in
Amicus Therapeutics Inc and bought 500,000 shares worth $4.82 million.
This means they effectively own approximately 0.1% of the company.
Amicus Therapeutics Inc makes up
5.5%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Epizyme Inc by buying
272,247 additional shares.
This makes their stake in Epizyme Inc total 836,802 shares worth $6.95 million.
Epizyme Inc dropped approximately 0.1% in the past year.
On the other hand, there are companies that Burrage Capital Management is getting rid of from its portfolio.
Burrage Capital Management closed its position in Protalix BioTherapeutics on 16th August 2021.
It sold the previously owned 2,125,585 shares for $9.48 million.
Jeff Crispen also disclosed a decreased stake in G1 Therapeutics Inc by 0.6%.
This leaves the value of the investment at $1.05 million and 47,708 shares.
One of the smallest hedge funds
The two most similar investment funds to Burrage Capital Management are Alpha Quant Advisors and First Reserve Gp Xiii Ltd. They manage $99.8 million and $99.8 million respectively.
Jeff Crispen investment strategy
Burrage Capital Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 88.7% of
the total portfolio value.
The fund focuses on investments in the United States as
68.2% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
5% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.84 billion.
The complete list of Burrage Capital Management trades based on 13F SEC filings
These positions were updated on August 16th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Biocryst Pharmaceuticals Inc. |
No change
864,916
|
$13,674,000 | 13.71% |
| Intellia Therapeutics Inc |
No change
63,634
|
$10,303,000 | 10.33% |
| Protalix BioTherapeutics Inc. |
Closed
2,125,585
|
$9,480,000 | |
| PTC Therapeutics Inc |
Closed
160,372
|
$7,594,000 | |
| Epizyme Inc |
48.22%
836,802
|
$6,954,000 | 6.97% |
| Essa Pharma Inc |
No change
237,442
|
$6,784,000 | 6.80% |
| Neogenomics Inc. |
No change
147,921
|
$6,682,000 | 6.70% |
| MEI Pharma Inc |
No change
2,331,313
|
$6,644,000 | 6.66% |
| Crinetics Pharmaceuticals In |
8.16%
294,620
|
$5,554,000 | 5.57% |
| Cytokinetics Inc |
No change
244,673
|
$4,842,000 | 4.85% |
| Amicus Therapeutics Inc |
Opened
500,000
|
$4,820,000 | 4.83% |
| Harmony Biosciences Hldgs In |
No change
150,000
|
$4,234,000 | 4.25% |
| Inozyme Pharma, Inc. |
43.10%
242,517
|
$4,132,000 | 4.14% |
| Cara Therapeutics Inc |
Closed
180,000
|
$3,908,000 | |
| Y-Mabs Therapeutics Inc |
No change
114,454
|
$3,869,000 | 3.88% |
| Fulcrum Therapeutics Inc |
Closed
319,819
|
$3,767,000 | |
| Mirum Pharmaceuticals Inc |
No change
205,866
|
$3,559,000 | 3.57% |
| Tricida Inc |
Closed
658,877
|
$3,485,000 | |
| Apellis Pharmaceuticals Inc |
Closed
80,727
|
$3,464,000 | |
| ADC Therapeutics SA |
No change
124,875
|
$3,041,000 | 3.05% |
| Verastem Inc |
Opened
705,585
|
$2,872,000 | 2.88% |
| Merus N.V |
No change
130,683
|
$2,753,000 | 2.76% |
| Geron Corp. |
No change
1,912,673
|
$2,697,000 | 2.70% |
| AvroBio Inc |
No change
244,920
|
$2,177,000 | 2.18% |
| Revolution Medicines Inc |
Opened
50,000
|
$1,587,000 | 1.59% |
| Black Diamond Therapeutics I |
No change
110,447
|
$1,346,000 | 1.35% |
| G1 Therapeutics Inc |
59.47%
47,708
|
$1,047,000 | 1.05% |
| Turning Point Therapeutics I |
97.00%
2,164
|
$169,000 | 0.17% |
| No transactions found | |||
| Showing first 500 out of 28 holdings | |||
Hedge funds similar to Burrage Capital Management
- Lesa Sroufe & Co
- Financial Management Concepts Corp adv
- Fairbanks Capital Management
- Friedman, Billings, Ramsey
- Cheyne Capital Management (uk) LL.P.
- First Reserve Gp Xiii Ltd
- Alpha Quant Advisors
- Chapwood Capital Investment Management
- Linden Rose Investment
- Bishop Street Capital Management
- Matthew 25 Management
- Coe Capital Management
- Billings Capital Management
- Fortress Wealth